Advancements in Muscle-Invasive Bladder Cancer Treatment and ctDNA Monitoring

This chapter covers key findings from the ASCO Annual Meeting on muscle-invasive bladder cancer, particularly the Niagara trial comparing gemcitabine-cisplatin with dervalumab. It also explores the role of ctDNA as a prognostic marker and discusses eligibility for cisplatin-based chemotherapy and the use of adjuvant immunotherapy.